Seeking Alpha

Endologix (ELGX +0.5%) receives premarket FDA approval for a broadened indication of it's 21Fr...

Endologix (ELGX +0.5%) receives premarket FDA approval for a broadened indication of it's 21Fr profile and smaller EVAR systems, including totally percutaneous endovascular aneurysm repair. The authorization is based on the successful outcome of it's first clinical trial, the PEVAR Trial.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|